

# Human LILRB1/CD85j/ILT2 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF2017

DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human LILRB1/CD85j/ILT2 in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant human (rh) ILT4 is observed and 15% cross-reactivity with rhILT5 is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	Mouse myeloma cell line NS0-derived recombinant human LILRB1/CD85j/ILT2 Gly24-His458 Accession # Q8NHL6		
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.		


### **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 μg/mL	Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera (Catalog # 2017-T2)
Flow Cytometry	2.5 µg/10 <sup>6</sup> cells	Human whole blood monocytes
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	
Neutralization	Measured by its ability to neutralize LILRB1/CD85j/ILT2-mediated adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line. Cosman, D. <i>et al.</i> (1997) Immunity 7:273. The Neutralization Dose (ND <sub>50</sub> ) is typically 0.3-1.0 μg/mL in the presence of 5 μg/mL Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera.	

### DATA

### Neutralization



Cell Adhesion Mediated by LILRB1/CD85j/ILT2 and Neutralization by Human LILRB1/CD85j/ILT2 Antibody. Recombinant Human LILRB1/CD85j/ILT2j Fc Chimera (Catalog # 2017-T2), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera (5 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB1/CD85j/ILT2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2017). The ND<sub>50</sub> is typically 0.3-1.0 µg/mL.

## PREPARATION AND STORAGE

**Reconstitution** Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

\*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

#### 

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Rev. 2/6/2018 Page 1 of 2





# Human LILRB1/CD85j/ILT2 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF2017

### BACKGROUND

The immunoglobulin-like transcript (ILT) family of activating and inhibitory type immunoreceptors are expressed on many leukocyte subsets and function in the regulation of immune responses (1-3). This family was also named leukocyte Ig-like receptors (LIR) and monocyte/macrophage Ig-like receptors (MIR). ILTs share significant homology with killer cell Ig-like receptors (KIR). The ILT genes are located on human chromosome 19q13.4 in the leukocyte receptor complex, which also include the genes encoding KIRs (4). With the exception of ILT-6, which is a soluble molecule, all ILT family members are type I transmembrane proteins having two or four extracellular Ig-like domains (2, 3). One subset of the ILT receptors (referred to as subfamily B of the LIRs) has long cytoplasmic tails containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events by recruiting SH2-containing protein tyrosine phosphatase-1. Another subset of the ILT receptors (referred to as subfamily A of the LIRs) contains activating receptors with short cytoplasmic regions that lack signal transduction motifs. These receptors contain a basic arginine residue within their transmembrane domains, which allows association with Fc Ry, an immunoreceptor tyrosine-based activation motif (ITAM)-bearing signal adapter protein (1-3).

ILT2, also known as LIR1, MIR7, and CD85j, is expressed on most monocytes, dendritic cells, and mature B cells (1-3). It is also expressed on small percentages of T cells and NK cells. ILT2 has four extracellular Ig-like domains and three cytoplasmic ITIMs. It functions as an inhibitory receptor that prevents cellular activation. ILT2 has been shown to bind classical (HLA-A and -B) and nonclassical (HLA-G1, -E and -F) MHC class I molecules (MHCI) (1-3). ILT2 also binds with high affinity to an MHC class I homologue from human cytomegalovirus (3). Ligation of ILT2 by MHC class I may function to poise cellular activation thresholds and inhibit various leukocyte effector mechanisms that are regulated by MHC class I molecules on target cells.

### References:

- 1. Allen, D. et al. (2000) Immunobiol. 202:34.
- 2. Colonna, M. et al. (1999) J. Leukocyte Biol. 66:375.
- 3. Borges, L. and D. Cosman (2000) Cytokine Growth Factor Rev. 11:209.
- 4. Young, N. et al. (2001) Immunogenetics 53:270.

